Uploaded August 2023 | Updated November 2026, 1 day ago
The quest for an effective Alzheimer's treatment continues as recent trials of solanezumab, a monoclonal antibody targeting monomeric amyloid, yield disappointing results in slowing cognitive decline. Original Article: nejm.org/doi/full/10.1056/NEJMoa2305032
State of Health Podcast: open.spotify.com/show/7JWc9FSny48WVhYr0GgBbn
Join this channel to get access to perks:
youtube.com/channel/UCUqgkmGj16aRxmVlHnDdVbw/join
The quest for an effective Alzheimer's treatment continues as recent trials of solanezumab, a monoclonal antibody targeting monomeric amyloid, yield disappointing results in slowing cognitive decline. Original Article: nejm.org/doi/full/10.1056/NEJMoa2305032
State of Health Podcast: open.spotify.com/show/7JWc9FSny48WVhYr0GgBbn
Join this channel to get access to perks:
youtube.com/channel/UCUqgkmGj16aRxmVlHnDdVbw/join










